T-Cell Acute Lymphoblastic Leukemia - Pipeline Insight, 2021

DelveInsights, T-Cell Acute Lymphoblastic Leukemia Pipeline Insight, 2021, report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in T-Cell Acute Lymphoblastic Leukemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
Global coverage

T-Cell Acute Lymphoblastic Leukemia Understanding
T-Cell Acute Lymphoblastic Leukemia: Overview
T-cell acute lymphoblastic leukaemia (T-ALL) is a type of acute leukaemia meaning that it is aggressive and progresses quickly. It affects the lymphoid-cell-producing stem cells, in paticular a type of white blood cell called T lymphocytes as opposed to acute lymphoblastic leukaemia (ALL) which commonly affects B lymphocytes. T-cell acute lymphoblastic leukemia (T-ALL) represents approximately 12% to 15% of all newly diagnosed ALL cases in pediatric patients and is noteworthy for its unique clinical and biological features. There are no specific signs or symptoms which would allow a diagnosis of T-ALL to be made. The most common signs and symptoms are caused by the bone marrow being unable to produce enough normal blood cells. Most T-ALL disease recurrences occur within 2 years of diagnosis, and relapsed disease remains very difficult to salvage, with survival rates lower than 25%. Patients with newly diagnosed T-ALL are typically treated with risk-based multiagent chemotherapy regimens for 2 to 3 years, with or without cranial radiation therapy (CRT).

"T-Cell Acute Lymphoblastic Leukemia - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the T-Cell Acute Lymphoblastic Leukemia pipeline landscape is provided which includes the disease overview and T-Cell Acute Lymphoblastic Leukemia treatment guidelines. The assessment part of the report embraces, in depth T-Cell Acute Lymphoblastic Leukemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, T-Cell Acute Lymphoblastic Leukemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence T-Cell Acute Lymphoblastic Leukemia R&D. The therapies under development are focused on novel approaches to treat/improve T-Cell Acute Lymphoblastic Leukemia.

T-Cell Acute Lymphoblastic Leukemia Emerging Drugs Chapters
This segment of the T-Cell Acute Lymphoblastic Leukemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
T-Cell Acute Lymphoblastic Leukemia Emerging Drugs
Isatuximab: Sanofi
Isatuximab (formerly SAR650984) is a humanized, IgG1-derived monoclonal antibody (mAb) produced from a Chinese hamster ovary (CHO) cell line. Structurally, isatuximab is comprised of two identical immunoglobulin kappa light chains and two identical immunoglobulin gamma heavy chains. It is a cytolytic antibody targeted against CD38, a glycoprotein found on the surface of some immune cells that is highly expressed by malignant plasma cells in multiple myeloma. Along with daratumumab, another anti-CD38 mAb, isatuximab constitutes a novel treatment modality for patients with difficult-to-treat multiple myeloma. The drug is currently being evaluated in Phase II stage of development for the treatment of T-cell acute lymphoblastic leukemia.

CPX-351: Jazz Pharmaceuticals
Liposomal cytarabine-daunorubicin CPX-351 combines two chemotherapy drugs that are known to help each other work better, and may work to stop the growth of cancer cells by blocking the cells from dividing. The notable clinical efficacy of CPX-351 is achieved through maintenance of a synergistic 5:1 molar ratio of cytarabine and daunorubicin within the liposome after intravenous injection. It is being evaluated in Phase II clinical trial to treat T-cell acute lymphoblastic leukemia.
Further product details are provided in the report..

T-Cell Acute Lymphoblastic Leukemia: Therapeutic Assessment
This segment of the report provides insights about the different T-Cell Acute Lymphoblastic Leukemia drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in T-Cell Acute Lymphoblastic Leukemia
There are approx. 12+ key companies which are developing the therapies for T-Cell Acute Lymphoblastic Leukemia. The companies which have their T-Cell Acute Lymphoblastic Leukemia drug candidates in the most advanced stage, i.e. Phase II include, Sanofi.
Phases
DelveInsights report covers around 12+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Route of Administration
T-Cell Acute Lymphoblastic Leukemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Parenteral
Intravenous
Subcutaneous
Topical.
Molecule Type

Products have been categorized under various Molecule types such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

T-Cell Acute Lymphoblastic Leukemia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses T-Cell Acute Lymphoblastic Leukemia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging T-Cell Acute Lymphoblastic Leukemia drugs.

T-Cell Acute Lymphoblastic Leukemia Report Insights
T-Cell Acute Lymphoblastic Leukemia Pipeline Analysis
Therapeutic Assessment
Unmet Needs
Impact of Drugs

T-Cell Acute Lymphoblastic Leukemia Report Assessment
Pipeline Product Profiles
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
How many companies are developing T-Cell Acute Lymphoblastic Leukemia drugs?
How many T-Cell Acute Lymphoblastic Leukemia drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of T-Cell Acute Lymphoblastic Leukemia?
What are the key collaborations (IndustryIndustry, IndustryAcademia), Mergers and acquisitions, licensing activities related to the T-Cell Acute Lymphoblastic Leukemia therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for T-Cell Acute Lymphoblastic Leukemia and their status?
What are the key designations that have been granted to the emerging drugs?

Introduction
Executive Summary
T-Cell Acute Lymphoblastic Leukemia: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
Isatuximab: Sanofi
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early stage products (Phase I)
Comparative Analysis
CD7 CAR T cells: iCell Gene Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
T-Cell Acute Lymphoblastic Leukemia Key Companies
T-Cell Acute Lymphoblastic Leukemia Key Products
T-Cell Acute Lymphoblastic Leukemia- Unmet Needs
T-Cell Acute Lymphoblastic Leukemia- Market Drivers and Barriers
T-Cell Acute Lymphoblastic Leukemia- Future Perspectives and Conclusion
T-Cell Acute Lymphoblastic Leukemia Analyst Views
T-Cell Acute Lymphoblastic Leukemia Key Companies
Appendix

List Of Tables

Table 1 Total Products for T-Cell Acute Lymphoblastic Leukemia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List Of Figures

Figure 1 Total Products for T-Cell Acute Lymphoblastic Leukemia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Select Country Albania Algeria Afghanistan Angola Argentina Armenia Aruba Australia Austria Azerbaijan Andorra Anguilla Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Bosnia Cambodia Cameroon Central African Republic Chad Chile China Colombia Comoros Congo (Brazzaville) Cook Islands Costa Rica Cote d Ivoire Croatia Cuba Cyprus Czech Republic Cayman Islands Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Gibraltar Greece Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Herzegovina Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Korea Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Lithuania Luxembourg Liechtenstein Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Middle East & North Africa (MENA) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Palau Palestinian Territories Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Palestine Qatar Romania Russia Rwanda Samoa Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka Saint Kitts and Nevis Saint Vincent and the Grenadines Sudan Suriname Swaziland Sweden Switzerland Syria Scotland San Marino Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America Uruguay Uzbekistan Uraguay Vanuatu Venezuela Vietnam Virgin Islands Yemen Zambia Zimbabwe Canada Grenada Cape Verde Belize Curacao Republic of Srpska Antigua and Barbuda Saint Lucia Falkland Islands Faroe Islands Federated States of Micronesia Guadeloupe Martinique Montserrat Niue

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available